** Shares of AIM Vaccine Co Ltd 6660.HK jump as much as 13.2% to HK$6.35; on course for biggest one-day gain since October 17, 2024
** Stock on track for the second session of gain
** AIM says U.S. Food and Drug Administration (FDA) has approved its application for clinical trial of mRNA respiratory syncytial virus vaccines
** The Chinese mRNA vaccine products developer says it is U.S. FDA's first approval for the company's products, marking a "significant progress" for its global strategy
** Hang Seng Commerce & Industry Index .HSNC and Hang Seng Index .HSI both add 0.1%, healthcare index .HSCIH gains 0.2%
** Stock up 1.5% YTD
(Reporting by Donny Kwok)
((donny.kwok@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。